Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (26677)	11/25/1998 12:46:00 PM
From: aknahow	Read Replies (1) \| Respond to of 32384

Why? If double blinding, during the trial stage, is so important to reduce or attempt to eliminate any bias, why at the review stage load the bias factor by including lay people on the panel? Even worse are those impacted by the disease to be treated by the drug under review. I really think that most of the time people like myself would favor approval, and perhaps that is why there is no, big, protest by the drug companies. I thought the process of review for other than safety was wrong and now I just am more convinced that it is.